<DOC>
	<DOCNO>NCT00969150</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability Levomilnacipran ER versus placebo treatment outpatient major depressive disorder .</brief_summary>
	<brief_title>Safety Efficacy Levomilnacipran ER ( F2695 SR ) Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men woman , 1880 year old Currently meet DSMIVTR criterion Major Depressive Disorder The patient 's current depressive episode must least 4 week duration Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control Patients history meeting DSMIVTR criterion : manic hypomanic episode schizophrenia psychotic disorder obsessivecompulsive disorder Patients consider suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>